FDA accepts A.P. Pharma’s resubmission of NDA for APF530

Published on October 17, 2012 at 2:29 AM · No Comments

A.P. Pharma, Inc. (OTCBB: APPA), a specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company's resubmission of its New Drug Application (NDA) for APF530. The FDA has set a Prescription Drug User Fee Act (PDUFA) action date of March 27, 2013. APF530 is a long-acting formulation of granisetron and is being developed for the prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV).

"The acceptance of our New Drug Application for APF530 represents an important step towards providing physicians and patients with a potential new long-acting therapeutic agent to combat the debilitating side effects of nausea and vomiting associated with many chemotherapy treatments," said John B. Whelan, A.P. Pharma's president and chief executive officer. "We will continue working with the FDA as it reviews our NDA submission, recognizing the important role APF530 could play in reducing chemotherapy treatment side effects for cancer patients."

A.P. Pharma's NDA for APF530, which was resubmitted to the FDA on September 27, 2012, seeks approval to market and sell APF530 in the United States for the prevention of acute- and delayed-onset CINV. The NDA was submitted under section 505(b)(2) of the Federal Food, Drug and Cosmetic Act, whereby the Company can rely upon the FDA's prior safety and efficacy findings for APF530's active ingredient, granisetron.

Source:

A.P. Pharma, Inc.

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Janssen announces submission of IMBRUVICA sNDA to FDA for WM treatment